Investment Rating - The investment rating for the company is "Buy" (maintained) [1][9]. Core Views - The report emphasizes the company's dual-track strategy in the medical and consumer sectors, highlighting the synergistic advantages that are expected to drive growth [8]. - The company is focused on enhancing its brand image and operational efficiency through a multi-channel approach, particularly leveraging online sales [5][6]. - The report anticipates a gradual recovery in the medical sector as the impact of the pandemic diminishes, with expectations for continued revenue growth in both medical and consumer segments [8]. Financial Performance and Projections - The company reported a total market capitalization of approximately 21.92 billion yuan and a circulating market capitalization of about 21.90 billion yuan as of September 26, 2025 [3]. - Revenue projections for the company are as follows: 2025 estimated revenue of 115.08 billion yuan, 2026 estimated revenue of 130.80 billion yuan, and 2027 estimated revenue of 148.47 billion yuan, reflecting growth rates of 28%, 14%, and 14% respectively [7][9]. - The forecasted net profit attributable to the parent company is expected to reach 9.95 billion yuan in 2025, 11.70 billion yuan in 2026, and 13.62 billion yuan in 2027, with corresponding growth rates of 43%, 18%, and 16% [7][9]. Strategic Focus - The company is committed to four strategic pillars: product leadership, operational excellence, brand enhancement, and global vision, focusing on key product categories such as cotton soft towels and medical consumables [5][6]. - The medical segment is expected to benefit from the aging population, driving demand for medical supplies and solutions, with a focus on high-margin products and optimizing product structure [5][6]. - The company has initiated overseas market expansion in Southeast Asia, Central Europe, and the Middle East, aiming to support growth in both domestic and international markets [5][6].